Bellevue Group Ag Biomarin Pharmaceutical Inc Transaction History

Bellevue Group Ag

  • $5.93 Billion
  • Q3 2024

A detailed history of Bellevue Group Ag transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Bellevue Group Ag holds 330,976 shares of BMRN stock, worth $21 Million. This represents 0.39% of its overall portfolio holdings.

Number of Shares
330,976
Previous 52,232 533.67%
Holding current value
$21 Million
Previous $4.3 Million 441.02%
% of portfolio
0.39%
Previous 0.07%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$69.02 - $93.84 $19.2 Million - $26.2 Million
278,744 Added 533.67%
330,976 $23.3 Million
Q2 2024

Aug 14, 2024
SELL
$74.43 - $92.22 $20.1 Million - $24.9 Million
-269,555 Reduced 83.77%
52,232 $4.3 Million
Q1 2024

May 15, 2024
SELL
$83.81 - $99.0 $334,318 - $394,911
-3,989 Reduced 1.22%
321,787 $28.1 Million
Q4 2023

Feb 14, 2024
SELL
$76.22 - $98.51 $1.84 Million - $2.38 Million
-24,112 Reduced 6.89%
325,776 $31.4 Million
Q3 2023

Nov 14, 2023
SELL
$85.07 - $94.48 $911,610 - $1.01 Million
-10,716 Reduced 2.97%
349,888 $31 Million
Q2 2023

Aug 14, 2023
BUY
$86.68 - $100.3 $27.1 Million - $31.3 Million
312,159 Added 644.36%
360,604 $31.3 Million
Q1 2023

May 15, 2023
SELL
$87.74 - $117.27 $1.07 Million - $1.44 Million
-12,240 Reduced 20.17%
48,445 $4.71 Million
Q4 2022

Feb 14, 2023
BUY
$80.93 - $108.63 $582,048 - $781,266
7,192 Added 13.44%
60,685 $6.28 Million
Q3 2022

Nov 14, 2022
SELL
$82.16 - $96.94 $1.66 Million - $1.96 Million
-20,260 Reduced 27.47%
53,493 $4.54 Million
Q2 2022

Aug 11, 2022
SELL
$71.48 - $86.85 $60,543 - $73,561
-847 Reduced 1.14%
73,753 $6.11 Million
Q1 2022

May 13, 2022
BUY
$74.28 - $92.69 $237,696 - $296,608
3,200 Added 4.48%
74,600 $5.75 Million
Q4 2021

Feb 10, 2022
BUY
$71.72 - $91.47 $1.41 Million - $1.8 Million
19,700 Added 38.1%
71,400 $6.31 Million
Q3 2021

Nov 12, 2021
BUY
$74.77 - $85.47 $837,424 - $957,264
11,200 Added 27.65%
51,700 $4 Million
Q2 2021

Aug 12, 2021
BUY
$75.51 - $84.79 $264,285 - $296,765
3,500 Added 9.46%
40,500 $3.38 Million
Q1 2021

May 12, 2021
BUY
$74.73 - $90.69 $2.77 Million - $3.36 Million
37,000 New
37,000 $2.79 Million
Q3 2020

Nov 16, 2020
SELL
$71.87 - $131.03 $5.53 Million - $10.1 Million
-76,900 Closed
0 $0
Q2 2020

Aug 13, 2020
BUY
$79.55 - $124.22 $381,840 - $596,256
4,800 Added 6.66%
76,900 $9.49 Million
Q1 2020

May 14, 2020
BUY
$71.37 - $96.85 $349,713 - $474,565
4,900 Added 7.29%
72,100 $6.09 Million
Q4 2019

Feb 14, 2020
BUY
$64.27 - $86.37 $4.32 Million - $5.8 Million
67,200 New
67,200 $5.68 Million
Q1 2019

May 15, 2019
SELL
$84.2 - $98.62 $3.87 Million - $4.53 Million
-45,969 Closed
0 $0
Q4 2018

Feb 12, 2019
SELL
$80.14 - $106.07 $152,266 - $201,533
-1,900 Reduced 3.97%
45,969 $3.91 Million
Q3 2018

Nov 13, 2018
SELL
$93.92 - $105.72 $154,968 - $174,438
-1,650 Reduced 3.33%
47,869 $4.64 Million
Q2 2018

Aug 07, 2018
BUY
$76.01 - $99.03 $392,895 - $511,886
5,169 Added 11.66%
49,519 $4.67 Million
Q1 2018

May 09, 2018
SELL
$77.67 - $92.63 $54,369 - $64,841
-700 Reduced 1.55%
44,350 $3.6 Million
Q4 2017

Feb 14, 2018
SELL
$80.76 - $95.13 $302,850 - $356,737
-3,750 Reduced 7.68%
45,050 $4.02 Million
Q3 2017

Nov 13, 2017
SELL
$80.6 - $94.95 $1.31 Million - $1.54 Million
-16,200 Reduced 24.92%
48,800 $4.54 Million
Q2 2017

Aug 14, 2017
BUY
N/A
65,000
65,000 $5.9 Million

Others Institutions Holding BMRN

# of Institutions
635
Shares Held
178M
Call Options Held
2.01M
Put Options Held
1.28M
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email